University of Southern California, Los Angeles, CA
Adam Kolawa , Siddharth Iyengar , Justin Wayne Wong Tiu-lim , Angel Arizpe , Elizabeth Pan , Irene Chen , Stefani Frost , Siamak Daneshmand , Anne K. Schuckman , Hooman Djaladat , David I. Quinn , Varsha Tulpule , James S. Hu , Victoria K. Cortessis , Anishka D'souza
Background: Testicular germ cell tumors (TGCTs) is the leading solid-organ malignancy of adolescent/young adult males. Incidence is rising in all racial/ethnic groups, and most rapidly in Hispanics, who tend to be younger than non-Hispanic white (NHW) patients at diagnosis yet have poorer survival. Understanding these disparities is an urgent research priority, but granular prognostic information is inadequate in large population-based registries. We therefore initiated an investigation of a largely Hispanic clinical cohort. Methods: We identified consecutive patients with pathologically confirmed TGCT treated from 2015 to 2020 at two major referral centers in the US, with a large Hispanic population (the Los Angeles General Medical and USC/Norris Comprehensive Cancer Centers) and collected detailed features of demography, clinical presentation, treatment, and outcome into a structured RedCAP database. We used chi-square, Fisher exact, and Mann-Whitney U tests to compare established prognostic features between Hispanic and NHW patients. Results: Among 27 NHW and 75 Hispanic patients, Hispanics were younger at diagnosis (median 27 vs 30 years, p=0.5), diagnosed less frequently with pure seminoma (12% vs 23%, p=0.19), and experienced shorter time to first progression (median 8.5 vs 19 months, p=0.6). Among non-seminoma patients, Hispanics had higher probability of IGCCCG intermediate risk (26% vs 0%, p=0.03) but similar frequency of poor risk disease (Table). Accordingly, Hispanics had more regional lymph node involvement at presentation (48% vs 19%, p=0.03) but comparable frequency of visceral metastasis. Conclusions: Hispanic patients had adverse features already evident in population-based data, and novel findings of higher risk stratification and greater lymph node involvement than NHWs. Expansion of clinical series will be vital to identifying factors and processes that underlie adverse presentation and outcomes of Hispanics with TGCT, and to refining guidelines for care of the growing population of Hispanic patients with TGCT.
Baseline patienta characteristics. | ||||
---|---|---|---|---|
Characteristic | Non-Hispanic White | Hispanic | p | |
Pure seminoma | 6(23%) | 9(12%) | 0.19c | |
Good riskb | 5(83%) | 7(70%) | 0.30c | |
Intermediate riskb | 1(17%) | 0(0%) | ||
Non-seminoma | 20(77%) | 64(88%) | ||
Good riskb | 14(70%) | 34(53%) | 0.03d | |
Intermediate riskb | 0(0%) | 16(26%) | ||
Poor riskb | 5(25%) | 13(21%) | ||
Lymph node metastasis | 5(19%) | 35(48%) | 0.03 |
a3 had missing data. bIGCCCG risk category. cComparing histology between Hispanic and NHW patients. dComparing risk category within histology.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2022 ASCO Annual Meeting
First Author: ANKUR NANDAN VARSHNEY
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Peng Zhang
2023 ASCO Quality Care Symposium
First Author: Sapna Kedia
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Sharon Hechter